Mastek Limited — Q4 FY25 earnings call

Call held 21 Apr 2025

Management summary

Mastek reported strong annual performance for FY25 with double-digit revenue and net profit growth, driven by robust UK & Europe and Oracle business. However, Q4 saw a dip in profitability and North America revenue due to one-time costs, lower-margin new capabilities, and macro uncertainties. The company is strategically resetting its US operations, focusing on Data & AI, and driving operational efficiencies to restore margins and sustain growth in FY26.

Highlights

  • Overall revenue from operations for FY25 grew by 13.1%.

  • Net profit for FY25 grew by 20.9% compared to FY24.

  • Total cash and cash equivalent increased to INR 622 crores from INR 473 crores last year.

  • UK and Europe core business had a phenomenal quarter, with UK revenue growing over 17.2% YoY and 9.4% QoQ.

  • Oracle business grew more than 50% YoY, showing strong momentum.

Concerns

  • Overall EBITDA de-grew by 1.4% in Q4.

  • Net profit de-grew by 14.4% in Q4, largely due to a one-time prior period cost adjustment.

  • North America business saw an 8% QoQ drop in revenue.

  • 12-month order backlog grew only 1.7% for the year (adjusted to 7-8% with a late deal).

  • UK margins dipped due to investments in newer Data & AI capabilities, on-site resources, and subcontractor costs.

Key financials

3 periods

Headline

  • Cash & Equivalents
    ₹622 Cr

Q4

  • EBITDA Growth
    -1.4%
  • Net Profit Growth
    -14.4%

FY25

  • Revenue Growth
    13.1%
  • Net Profit Growth
    20.9%

What they filed

Q1 FY27: revenue up 7.7%, net profit up 15.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue867 870 905 915 940 +8%906 +4%938 +4%985 +8%
EBITDA143 141 139 137 146 +2%152 +8%151 +9%151 +10%
Net profit129 95 81 92 97 −25%108 +14%106 +31%106 +15%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentRevenue Growth YoYRevenue Growth QoQ
UK & Europe17.2%9.4%
North America16%-8%
Oracle Business50%—

Order book

high confidence

Execution

healthy runway for the next 2 years

Pipeline

deal pipeline tcv

Adjusted 12-month backlog including a $15 million deal closed in early April.

The overall backlog has definitely increased, with efforts to secure long-term contracts. The reported 12-month backlog growth of 1.7% YoY is understated due to a $15 million deal closing just after quarter-end, which would bring the growth to 7-8% YoY and ~12% QoQ.

Source: Prepared remarks

Capital allocation

high confidence
  • Dividend ₹16/share (final)
    For this year, we have also declared a final dividend of INR 16, which makes up a cumulative dividend of 460% for the year.
  • Liquidity Cash ₹622 Cr Total cash and cash equivalent increased from INR 473 crores at the end of last year to INR 622 crores.
    The total cash and cash equivalent that we had in the company has now grown to INR 622 crores as compared to INR 473 crores that we had at the end of last year.

Guidance & targets

Profitability

  • EBITDA Margin Profitability · FY26 · High confidence 17-19%
    Our ambition and drive is to drive to 17% to 19%. Like I said, there are some fundamental correction that we have made now. A lot of it is a cost of reset also. Some of it is also driving business in the right capability areas in U.K. as well as in U.S. So these will need some fundamental time to correct. But I'm sure before we end the next year, we will be in that range of 17% to 19%.

    — Umang Nahata

Revenue

  • UK Healthcare Growth Revenue · FY26 · Medium confidence High growth
    healthcare continues to be a strong momentum in the U.K. We also feel that the more than 100% growth that we have had in healthcare in U.K. last year will continue to offer a significantly high growth even in the coming fiscal year, which is FY'26.

    — Umang Nahata

Headcount

  • Data AI Team Growth Headcount · Ongoing · High confidence Adding 50-100 people QoQ
    So our current Data AI team, is around 200, 250-plus people, but it is growing as we speak, growing quarter-on-quarter. So we're adding another 50-100 people.

    — Umang Nahata

Operational Efficiency

  • AI Adoption Efficiency Operational Efficiency · Ongoing · High confidence 15-20% efficiency
    Third is adoption of AI in all of our internal delivery programs, especially the ones which are fixed bid delivery programs. And we are looking forward to anywhere between a 15% to 20% efficiency drive just because of AI adoption in our business.

    — Umang Nahata

  • Customer Efficiency (Legacy Modernization) Operational Efficiency · Ongoing · High confidence 30-50% efficiency
    So we now have an AI-led sales force implementation as well as an AI-led legacy modernization platform that allows us to offer anywhere between 30% to 50% efficiency to our customers to execute much faster

    — Umang Nahata

What to watch in Q1 FY26

UK Segment Margin Recovery

next quarter / midterm (FY26)
Current Dipped in Q4 FY25
Target Signs of improvement towards 17-19% range

Why it matters

UK is a core growth driver, and margin recovery is crucial for overall profitability targets.

As we build capabilities, as we also expand into more offshoring into these lines of businesses, I think the margins will come back to the healthy rate that we had earlier. In the short term, we might see some impact to margin.

Risks & concerns

  • Macro changes and uncertainty in US market

    medium

    Impacts include in-sourcing by clients, shift in deal momentum, budget cuts, and slowdown in execution/spend, causing an 8% QoQ drop in US revenue.

    The macro changes in the U.S., as we all know, is showing some impact or some near-term impact in our business as it is... some of our customers are more directly impacted because of these policies, which has led to in-sourcing of some businesses by them or in-sourcing of some work as well as a right shift in the deal momentum that we were working with.

    Management acknowledged

  • Margin compression from new capabilities and on-site delivery

    medium

    Growth in newer skills like Data & AI and front-ending capabilities, especially in the UK, requires on-site resources and subcontractor engagement, leading to lower initial margins.

    The growth that we are seeing in our U.K. business... is in more newer skills, is more in Data & AI capabilities and in more front-ending capabilities. Some of these capabilities, we are also building as we deliver. And therefore, the margins in these businesses are lower as compared to our traditional margins that we used to enjoy.

    Management acknowledged

  • One-time costs from organizational reset

    low

    People changes and organizational restructuring led to one-time costs in Q4, with potential for more in Q1 FY26.

    There's also a reset in terms of people changes that we are executing, quite a few across the organization. And that reset has also led to some one-time costs that have come in this quarter and we might see some more as we look forward into Q1.

    Management acknowledged

  • Timing mismatch in deal closures affecting reported backlog

    low

    A $15 million ACV contract closed in early April was not included in the Q4 12-month backlog, making the reported 1.7% YoY growth seem lower than actual.

    there's almost a $15 million worth of contract, which based on our cycle has closed in the first week of April, which we haven't counted there... So I would say, there is some timing mismatch in terms of the deal closing that we were looking forward to.

    Management downplayed

Q&A highlights

6 direct
UK Margin Decline and Recovery Partial
As we build capabilities, as we also expand into more offshoring into these lines of businesses, I think the margins will come back to the healthy rate that we had earlier. In the short term, we might see some impact to margin.

Analyst challenged the significant drop in UK margins, and management explained the reasons (new capabilities, on-site work, subcontractors) and outlined the path to recovery, indicating short-term pressure but midterm improvement.

Asked by Jalaj

12-Month Order Backlog Growth Direct
there's almost a $15 million worth of contract, which based on our cycle has closed in the first week of April, which we haven't counted there... if I add that $15 million, then the 12-month backlog also moves more close to 7% to 8% on an annual basis as well as approximately around 12% on a quarter-on-quarter basis.

Analyst questioned the low 1.7% YoY backlog growth, and management provided a crucial clarification about a significant deal that closed post-quarter, adjusting the effective growth rate upwards.

Asked by Jalaj

US Business Strategy and Macro Impact Direct
we relooked at all of our U.S. focus and strategy... first and foremost change is trying to simplify the org structure and make the organization one single consolidated North America business... The second part is to really focus on capabilities that are growing and that continue to see a lot of demand and growth, which is largely around Data & AI.

Analyst probed the US business decline and management detailed a comprehensive strategic reset for the region, acknowledging macro challenges and outlining a focus on organizational simplification and Data & AI capabilities.

Asked by Jalaj

Overall EBITDA Margin Target Direct
No, that doesn't change at all. Our ambition and drive is to drive to 17% to 19%... But I'm sure before we end the next year, we will be in that range of 17% to 19%.

Analyst sought confirmation on the company's long-term EBITDA margin target, and management reaffirmed the 17-19% range for FY26, providing clarity on profitability expectations despite current dips.

Asked by Jalaj

NHS England Merger Impact Direct
the merger of NHS England into Department of Health that got announced earlier in the quarter, currently, this process is going to be a steady long-term process. It will take at least 2 years for the government to really integrate and put the 2 departments together... we are optimistic for a significant growth even in the next year.

Analyst asked about potential disruption from the NHS merger, and management clarified it's a long-term integration process with no immediate impact on demand, maintaining optimism for continued growth.

Asked by Amit Chandra

AI Adoption and Productivity Benefits Direct
we are working closely with all of our existing install base customers to see how we can help them use AI to drive a far more degree of modernization... we are working with them to pass around 30% efficiency back to them also. But I think we will still be profitable in spite of passing the 30% efficiency back to them.

Analyst questioned if customers are committing to AI-driven productivity benefits, and management confirmed active engagement, highlighting significant efficiency gains for clients while maintaining profitability for Mastek.

Asked by Ravi Menon

Operational Efficiency Program Details Direct
The first step was around driving internal efficiency overhead cost management... The second is simplification of the organization structure... Third is adoption of AI in all of our internal delivery programs... And last and not the least is reorganizing our business to deliver the kind of growth that we have set in U.K.

Analyst asked about the process to improve margins, and management provided a detailed 4-5 step operational efficiency program, offering insight into the company's strategy for FY26 profitability.

Asked by Ngn Puranik

Working Capital and DSO Partial
I think our DSOs have improved. In fact, it has come down to 83 days in this quarter, which has been our target that we have set ourselves up for the fiscal. So overall, we see a healthy working capital balance and we feel quite comfortable with the cash generation that we have.

Analyst raised a concern about increased trade receivables and DSOs, but management countered that DSOs have improved to 83 days and the company maintains a healthy working capital and cash generation, providing reassurance.

Asked by Varun Kulkarni

3 min read 7 chapters

Detailed narrative

Strong Annual Performance Despite Q4 Headwinds

Mastek concluded FY25 with robust annual growth, reporting a 13.1% increase in revenue from operations and a 20.9% rise in net profit compared to FY24. The company's cash and cash equivalents also saw a significant boost, growing to INR 622 crores from INR 473 crores at the end of the previous year. However, Q4 FY25 presented some challenges, with overall EBITDA de-growing by 1.4% and net profit declining by 14.4%, primarily attributed to a one-time prior period cost adjustment and investments in new capabilities.

UK & Europe Business Drives Growth

The UK and Europe core business demonstrated exceptional performance, with UK revenue growing over 17.2% year-on-year and 9.4% quarter-on-quarter. This growth was fueled by strong digital services, Data & AI momentum, and significant traction in the healthcare sector, where the UK healthcare business grew over 100% in FY25. The company also successfully renewed large backlogs in secured government services, providing a healthy runway for the next two years and positioning for net new growth.

North America Undergoing Strategic Reset

The North America business experienced a mixed quarter, with a 16% year-on-year growth but an 8% quarter-on-quarter drop in revenue. This decline is linked to macro changes in the US, including client in-sourcing and shifts in deal momentum. Mastek is implementing a strategic reset in the region, focusing on simplifying its organizational structure, consolidating its North America business, and disproportionately investing in Data & AI capabilities to build long-term value, acknowledging that these changes will take time to yield full results.

Profitability and Margin Management

The Q4 profitability dip, with EBITDA de-growth of 1.4% and net profit de-growth of 14.4%, was primarily due to the initial lower margins associated with newer Data & AI capabilities, increased on-site resource costs, and one-time organizational reset expenses. Management reaffirmed its ambition to achieve an EBITDA margin of 17-19% by the end of FY26, driven by operational efficiency initiatives and the maturation of new capabilities. The company is confident that overall EBITDA will continue to grow in a healthy direction.

Data & AI as a Key Growth and Efficiency Driver

Data & AI is identified as a critical area for future growth and efficiency across all geographies. Mastek's Data AI team, currently 200-250+ people, is expanding by 50-100 people quarter-on-quarter. The ADOPT.AI platform has been extended to all service lines, enabling 30-50% efficiency for customers in legacy modernization. Internally, AI adoption in delivery programs is expected to drive 15-20% efficiency, contributing significantly to bottom-line performance in FY26.

Operational Efficiency and Organizational Changes

Mastek is undertaking a 4-5 step operational efficiency program for FY26. This includes internal efficiency and overhead cost management, simplification of the organizational structure (which incurred some one-time costs in Q4), AI adoption in internal delivery, and reorganizing the UK business to optimize resourcing and on-site/offshore mix. These initiatives are expected to drive robust and profitable growth, ensuring the company delivers healthy margins while meeting client demands for cost efficiency.

Shareholder Returns and Liquidity

For FY25, Mastek declared a final dividend of INR 16 per share, contributing to a cumulative dividend of 460% for the year. The company maintains a strong liquidity position, with total cash and cash equivalents growing to INR 622 crores. Management expressed comfort with the healthy working capital balance and consistent improvement in DSOs, which came down to 83 days in Q4, indicating strong cash generation.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Information Technology earnings calls